JP4195089B2 - 亜酸化物単位から製造される巨大環式化合物 - Google Patents

亜酸化物単位から製造される巨大環式化合物 Download PDF

Info

Publication number
JP4195089B2
JP4195089B2 JP52482597A JP52482597A JP4195089B2 JP 4195089 B2 JP4195089 B2 JP 4195089B2 JP 52482597 A JP52482597 A JP 52482597A JP 52482597 A JP52482597 A JP 52482597A JP 4195089 B2 JP4195089 B2 JP 4195089B2
Authority
JP
Japan
Prior art keywords
macrocyclic
com
active substance
present
substance according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP52482597A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000503015A5 (enExample
JP2000503015A (ja
Inventor
ケレック，フランツ
Original Assignee
ドナチュア ディーアール．ケレック ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ドナチュア ディーアール．ケレック ゲーエムベーハー filed Critical ドナチュア ディーアール．ケレック ゲーエムベーハー
Publication of JP2000503015A publication Critical patent/JP2000503015A/ja
Publication of JP2000503015A5 publication Critical patent/JP2000503015A5/ja
Application granted granted Critical
Publication of JP4195089B2 publication Critical patent/JP4195089B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/181—Heterocyclic compounds containing oxygen atoms as the only ring heteroatoms in the condensed system, e.g. Salinomycin, Septamycin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Rehabilitation Therapy (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
JP52482597A 1996-01-05 1996-12-30 亜酸化物単位から製造される巨大環式化合物 Expired - Fee Related JP4195089B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19600301A DE19600301C2 (de) 1996-01-05 1996-01-05 Durch Cyclooligomerisierung des einfachen Kohlensuboxids C¶3¶O¶2¶ aufgebaute makrocyclische Verbindungen, Verfahren zu deren Herstellung und Gewinnung sowie deren Verwendung
DE19600301.6 1996-01-05
PCT/EP1996/005867 WO1997025333A2 (en) 1996-01-05 1996-12-30 Macrocyclic compounds made from suboxide units

Publications (3)

Publication Number Publication Date
JP2000503015A JP2000503015A (ja) 2000-03-14
JP2000503015A5 JP2000503015A5 (enExample) 2008-08-21
JP4195089B2 true JP4195089B2 (ja) 2008-12-10

Family

ID=7782233

Family Applications (1)

Application Number Title Priority Date Filing Date
JP52482597A Expired - Fee Related JP4195089B2 (ja) 1996-01-05 1996-12-30 亜酸化物単位から製造される巨大環式化合物

Country Status (26)

Country Link
US (1) US6187810B1 (enExample)
EP (1) EP0874851B1 (enExample)
JP (1) JP4195089B2 (enExample)
KR (1) KR19990077000A (enExample)
CN (1) CN1209132A (enExample)
AR (1) AR005350A1 (enExample)
AT (1) ATE233768T1 (enExample)
AU (1) AU1307497A (enExample)
BG (1) BG102599A (enExample)
BR (1) BR9612430A (enExample)
CA (1) CA2241870A1 (enExample)
CZ (1) CZ208898A3 (enExample)
DE (2) DE19600301C2 (enExample)
EE (1) EE9800211A (enExample)
ES (1) ES2194128T3 (enExample)
HR (1) HRP970002A2 (enExample)
HU (1) HUP9904191A2 (enExample)
IL (1) IL125165A0 (enExample)
JO (1) JO1945B1 (enExample)
PL (1) PL327657A1 (enExample)
SI (1) SI0874851T1 (enExample)
SK (1) SK88598A3 (enExample)
TR (1) TR199801288T2 (enExample)
TW (1) TW376386B (enExample)
WO (1) WO1997025333A2 (enExample)
ZA (1) ZA9714B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO280796A0 (en) * 1996-10-07 1996-10-31 Austin Research Institute, The Methods of activating or enhancing FC receptors
DE10260537A1 (de) 2002-12-21 2004-07-15 Kerek, Franz, Dr. Peptide mit hohem Cysteingehalt
US20060067055A1 (en) * 2004-09-30 2006-03-30 Heffner Kenneth H Thermally conductive composite and uses for microelectronic packaging
US20080007890A1 (en) * 2004-09-30 2008-01-10 Harmon Julianne P Thermally conductive composite and uses for microelectronic packaging
CN119613750B (zh) * 2024-12-10 2025-08-12 杭州师范大学 一种机械及pH双重调控的蝶形钾离子通道分子及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2565115A (en) 1948-10-28 1951-08-21 Squibb & Sons Inc Method of obtaining a conjugated estrogen preparation
US2720483A (en) 1951-02-21 1955-10-11 Olin Mathieson Method of obtaining a conjugatedestrogen preparation

Also Published As

Publication number Publication date
DE69626548D1 (de) 2003-04-10
WO1997025333A2 (en) 1997-07-17
US6187810B1 (en) 2001-02-13
BR9612430A (pt) 1999-12-28
ES2194128T3 (es) 2003-11-16
SK88598A3 (en) 1998-12-02
AU1307497A (en) 1997-08-01
ZA9714B (en) 1997-07-23
DE69626548T2 (de) 2003-12-24
TR199801288T2 (xx) 1998-11-23
WO1997025333A3 (en) 1997-12-24
DE19600301C2 (de) 1999-12-09
PL327657A1 (en) 1998-12-21
TW376386B (en) 1999-12-11
SI0874851T1 (en) 2003-10-31
CN1209132A (zh) 1999-02-24
JO1945B1 (en) 1997-12-15
IL125165A0 (en) 1999-01-26
KR19990077000A (ko) 1999-10-25
CA2241870A1 (en) 1997-07-17
ATE233768T1 (de) 2003-03-15
HUP9904191A2 (hu) 2000-05-28
EP0874851B1 (en) 2003-03-05
AR005350A1 (es) 1999-04-28
JP2000503015A (ja) 2000-03-14
HRP970002A2 (en) 1998-04-30
BG102599A (en) 1999-03-31
EP0874851A2 (en) 1998-11-04
EE9800211A (et) 1998-12-15
DE19600301A1 (de) 1997-07-10
CZ208898A3 (cs) 1998-10-14

Similar Documents

Publication Publication Date Title
DE3836006C2 (de) Monophosphoryllipid-A-Derivate, Verfahren zur Herstellung von Monophosphoryllipid-A-Derivaten und Verwendung von Monophosphoryllipid-A-Derivaten
IKEKAwA et al. Antitumor activity of Hypsizigus marmoreus. I. Antitumor activity of extracts and polysaccharides
JP3286321B2 (ja) 新規なアミノステロール抗生物質
US6444706B2 (en) Guanidine derivatives, processes for preparing them and their use as pharmaceutical compositions
AU773038B2 (en) Aminosterol compounds and uses thereof
JP4195089B2 (ja) 亜酸化物単位から製造される巨大環式化合物
EP0792886A1 (en) Novel peptide and therapeutic agent
WO1991004258A1 (fr) Derive d'ionisotol et production de ce derive
WO2001049308A1 (en) Novel immune enhancing compositions
CN101161674B (zh) 一种环肽,其制备方法和其应用
CN113121627A (zh) 两性霉素b甲酯肽衍生物及其制备方法
JPH09104693A (ja) グリコシド類、グリコシドの無糖分解産物およびその誘導体
WO2020119773A1 (zh) 两性霉素b肽衍生物
JP2001316398A (ja) 抗アレルギー剤
JP2531487B2 (ja) 抗ｈｉｖ活性を有する新規な抽出物
JP2000103789A (ja) プロポリス由来のベンゾピラン誘導体の生理活性
JPH0686379B2 (ja) グルコ−ス耐性因子およびその製造方法
CN119119208A (zh) Buforin llb或其衍生肽作为ARF6抑制剂及应用
JPH06219974A (ja) 抗ウイルス性化合物
JPH02184699A (ja) “８−アミノ酸”に改良のある新規シクロスポリン誘導体
JP2000212196A (ja) 生理活性物質ｄｍ９８０９およびこれを有効成分とする医薬
JPH09143179A (ja) プロポリス由来のベンゾピラン誘導体
JPH01299264A (ja) 新規物質ｆｌ−６５７ｃ及びその製造法
JPS63307875A (ja) ハロサイアミンおよびその製造法
JP2006256984A (ja) ６−ヒドロキシスタウロスポリノンおよび５，６−ジヒドロキシアルキリアフラビンａ

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20031226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070619

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20070912

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20071022

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080611

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20080611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080704

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20080814

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080826

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20080925

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111003

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121003

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131003

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees